Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
路透社2026/10/06 13:21In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Additional stock information is included in paragraph 1; paragraphs 2 to 8 provide detailed information on the disease and clinical trial.
Reuters, October 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for the treatment of rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, sending the company's shares plunging 63% in premarket trading.
The therapy (firmonertinib) targets patients with previously untreated advanced non-small cell lung cancer (NSCLC) who carry a genetic alteration known as EGFR exon 20 insertion mutation, which may drive cancer growth.
This mutation accounts for about 0.5% to 1% of all NSCLC cases. Non-small cell lung cancer makes up about 85% of all lung cancer cases.
In the trial, according to an independent review, the 240-mg dose therapy developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months for the chemotherapy group.
Chief Executive Officer Bing Yao said the improvement in progression-free survival—that is, the time patients live without disease worsening or spreading—was not significant.
“These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion mutation NSCLC who are in urgent need of more effective treatment options.”
Yao said the company is evaluating the full data set to determine the most appropriate development path for firmonertinib.
ArriVent said no new safety signals were observed in the trial.
The therapy has already been approved in China for NSCLC patients carrying specific mutations.
(To assist non-English speakers, Reuters offers its reports through automated translation into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of this automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ICE brings futures trading to London’s $190 billion-a-day physical gold market
Precia reports 5,733,040 issued shares, 8,350,574 exercisable voting rights as of Aug. 31, 2026
Precia disclosed 5,733,040 issued shares as of Aug. 31, 2026. Theoretical voting rights totaled 8,677,204. Exercisable voting rights stood at 8,350,574, reflecting 326,630 treasury shares without voting rights. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precia SA published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
Asia FX: Tech-linked FX could outperform against US Dollar - MUFG
Sumitomo Metal expects global nickel market to stay in surplus in 2027
Crypto prices
More
